With Duchenne decision ahead, FDA's Marks pushes for speedy gene therapy approvals

Retrieved on: 2024-05-24 20:16:31

Tags for this article:

Biotechnology

Food and Drug Administration

Corvallis, Oregon

Sarepta Therapeutics

Duchenne muscular dystrophy

Gene therapy

Delandistrogene moxeparvovec

Accelerated approval

Peter Marks

Click the tags to see associated articles and topics

With Duchenne decision ahead, FDA's Marks pushes for speedy gene therapy approvals. View article details on hiswai:

Excerpt

Editors' picks. A thumbnail illustration for BioPharma Dive's IPO tracker Image attribution tooltip. Adeline Kon/BioPharma Dive. Image attribution ...

Article found on: www.biopharmadive.com

View Original Article